MCID: ATN003
MIFTS: 41

Autonomic Nervous System Neoplasm

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Autonomic Nervous System Neoplasm

MalaCards integrated aliases for Autonomic Nervous System Neoplasm:

Name: Autonomic Nervous System Neoplasm 12 14 69
Tumor of Autonomic Nervous System 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2621
NCIt 47 C5112
UMLS 69 C1332356

Summaries for Autonomic Nervous System Neoplasm

Disease Ontology : 12 A peripheral nervous system neoplasm that is located in the autonomic nervous system.

MalaCards based summary : Autonomic Nervous System Neoplasm, also known as tumor of autonomic nervous system, is related to neuroblastoma and glucocorticoid-induced osteoporosis. An important gene associated with Autonomic Nervous System Neoplasm is MYCN (MYCN Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Apoptosis Modulation and Signaling and Development HGF signaling pathway. The drugs Norepinephrine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include breast, prostate and lung, and related phenotypes are behavior/neurological and growth/size/body region

Related Diseases for Autonomic Nervous System Neoplasm

Diseases related to Autonomic Nervous System Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Related Disease Score Top Affiliating Genes
1 neuroblastoma 29.8 AKT1 ALK BACE1 CASP3 ENO2 MYC
2 glucocorticoid-induced osteoporosis 10.9 ALK TP53
3 water-clear cell adenoma 10.9 NGF NTRK1 TP53
4 rh isoimmunization 10.9 ENO2 NGF TP53
5 childhood medulloblastoma 10.9 ENO2 MYCN TP53
6 retroperitoneal neuroblastoma 10.9 MYCN VIP
7 olfactory neural tumor 10.8 ENO2 NGF TP53
8 ovary adenocarcinoma 10.8 MYCN VIP
9 neuropathy, hereditary sensory and autonomic, type v 10.8 NGF NTRK1
10 juxtacortical osteosarcoma 10.8 ENO2 MYC MYCN
11 skin hemangioma 10.8 MYC MYCN TP53
12 rhizomelic chondrodysplasia punctata, type 3 10.8 CASP3 TP53
13 accelerated tumor formation 10.8 BACE1 CASP3
14 febrile seizures, familial, 3b 10.8 NGF NTRK1 NTRK2
15 seminal vesicle cystadenoma 10.8 ENO2 MYCN
16 rhabdomyosarcoma 2, alveolar 10.8 ENO2 MYCN TH
17 heavy chain disease 10.8 AKT1 ENO2 TP53
18 gestational choriocarcinoma 10.8 AKT1 ENO2 TP53
19 integumentary system cancer 10.7 AKT1 CASP3 TP53
20 submandibular gland cancer 10.7 ENO2 TP53 VIP
21 primary malignant melanoma of the conjunctiva 10.7 AKT1 CASP3 MYC
22 fallopian tube adenomatoid tumor 10.7 ALK ENO2 MYCN NTRK2
23 vulvar keratoacanthoma-like carcinoma 10.7 ENO2 MYC MYCN TP53
24 pancreatic acinar cell adenocarcinoma 10.7 MFRP NGF PHOX2B
25 melanotic medulloblastoma 10.7 ENO2 MYC MYCN TP53
26 prostate rhabdomyosarcoma 10.7 ALK ENO2 MYCN TP53
27 idiopathic generalized epilepsy 10.7 CASP3 ENO2 NTRK2
28 non-distal trisomy 10q 10.6 ALK NTRK1 TP53
29 medullomyoblastoma 10.6 AKT1 CASP3 MYC TP53
30 trachea squamous cell carcinoma 10.6 AKT1 CASP3 MYC TP53
31 endotheliitis 10.6 ENO2 TH
32 bardet-biedl syndrome 10.6 AKT1 CASP3 MYC TP53
33 benign shuddering attacks 10.6 AKT1 ENO2 TP53 VIP
34 gallbladder cancer 10.6 AKT1 CASP3 MYC TP53
35 pharynx carcinoma in situ 10.6 ENO2 MYC MYCN NGF NTRK1
36 villous adenoma 10.6 AKT1 CASP3 MYC TP53
37 megakaryocytic leukemia 10.6 AKT1 CASP3 MYC TP53
38 prostate carcinoma in situ 10.6 BACE1 CASP3 MFRP NGF TH
39 hypersensitivity reaction type ii disease 10.6 ENO2 MYCN NTRK1 NTRK2 VIP
40 nodular goiter 10.6 AKT1 ALK ENO2 MYCN TP53
41 cavernous hemangioma 10.6 ENO2 MYCN NTRK1 NTRK2 VIP
42 ovarian cystadenocarcinoma 10.5 AKT1 BACE1 CASP3 NGF TH
43 cpt deficiency, hepatic, type ia 10.5 AKT1 CASP3 MYC TP53
44 atrial fibrillation, familial, 10 10.5 CASP3 NTRK2 PHOX2B TH
45 drug-induced hepatitis 10.5 ALK MYC TP53
46 eccrine papillary adenocarcinoma 10.5 ALK TP53
47 long qt syndrome 5 10.4 CASP3 NGF NTRK1 NTRK2 TH
48 nail disorder, nonsyndromic congenital, 1 10.4 CASP3 MYC TP53
49 leprosy 6 10.4 ENO2 TP53 VIP
50 pheochromocytoma 10.3 CASP3 ENO2 NGF NTRK1 TH VIP

Graphical network of the top 20 diseases related to Autonomic Nervous System Neoplasm:



Diseases related to Autonomic Nervous System Neoplasm

Symptoms & Phenotypes for Autonomic Nervous System Neoplasm

MGI Mouse Phenotypes related to Autonomic Nervous System Neoplasm:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 AKT1 ALK BACE1 CASP3 CNTN6 ENO2
2 growth/size/body region MP:0005378 10.36 AKT1 ALK BACE1 CASP3 ENO2 MYC
3 nervous system MP:0003631 10.31 ENO2 MFRP MYC MYCN NGF NTRK1
4 mortality/aging MP:0010768 10.3 AKT1 ALK BACE1 CASP3 MYC MYCN
5 cellular MP:0005384 10.26 CASP3 ENO2 MYC MYCN NTRK2 NUMBL
6 integument MP:0010771 10.13 AKT1 ALK BACE1 CASP3 MYC NGF
7 normal MP:0002873 10.1 AKT1 BACE1 MYC MYCN NGF NTRK1
8 muscle MP:0005369 10.03 AKT1 BACE1 CASP3 MYC MYCN NGF
9 hearing/vestibular/ear MP:0005377 9.97 CASP3 MYC NTRK1 NTRK2 NUMBL TP53
10 no phenotypic analysis MP:0003012 9.97 TP53 BACE1 CASP3 MYC MYCN NGF
11 reproductive system MP:0005389 9.81 AKT1 ALK CASP3 MYC MYCN NTRK2
12 pigmentation MP:0001186 9.73 ALK CASP3 MFRP MYC NTRK1 TP53
13 respiratory system MP:0005388 9.65 NTRK2 PHOX2B TH TP53 VIP AKT1
14 vision/eye MP:0005391 9.32 TP53 ALK CASP3 MFRP MYCN NGF

Drugs & Therapeutics for Autonomic Nervous System Neoplasm

Drugs for Autonomic Nervous System Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 834)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-41-2 439260
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
6
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 104987-11-3 445643 439492
7
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
8
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
9
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
10
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
11
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
12
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
13
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
14
Teniposide Approved Phase 4,Phase 2 29767-20-2 34698
15
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
16
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
17
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
18
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
19
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
20
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
21
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
22
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
23
Atropine Approved, Vet_approved Phase 4,Phase 3,Phase 2 5908-99-6, 51-55-8 174174
24
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
25
Terbutaline Approved Phase 4 23031-25-6 5403
26
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
27
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
28
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
29
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
30
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
32
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 63006 5281004
33
Ondansetron Approved Phase 4,Phase 3,Phase 2,Phase 1 99614-02-5 4595
34
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-75-2 4033
35
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
36
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1 537-46-2 10836
37
Citalopram Approved Phase 4,Phase 3,Phase 2,Early Phase 1 59729-33-8 2771
38
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
39
Granisetron Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 109889-09-0 3510
40
Everolimus Approved Phase 4,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
41
Tropisetron Approved, Investigational Phase 4,Phase 3,Phase 2 105826-92-4, 89565-68-4 5595
42
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
43
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326
44
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 170729-80-3 151165 6918365
45
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
46
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
47
Palonosetron Approved, Investigational Phase 4,Phase 3,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
48
Thioguanine Approved Phase 4,Phase 3,Phase 2 154-42-7 2723601
49
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
50
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1 172673-20-0 219090

Interventional clinical trials:

(show top 50) (show all 1743)

id Name Status NCT ID Phase Drugs
1 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
2 Palonosetron Associated to Aprepitant in Prophylaxis of PONV Unknown status NCT02431286 Phase 4 Aprepitant;Placebo;Dexamethasone
3 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
4 Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation Unknown status NCT00903188 Phase 4 cyclosporine;Everolimus
5 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4 tacrolimus OD, mycophenolic acid, prednisolone
6 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
7 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
8 Early Intervention for Erectile Dysfunction After Laparoscopic Resection for Rectal Cancer Completed NCT01912586 Phase 4
9 Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Completed NCT01298193 Phase 4 Aprepitant
10 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
11 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
12 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
13 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
14 Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment Completed NCT00536172 Phase 4 Escitalopram;Placebo
15 Pinverin Application Trial to Reduce Bowel Uptake of FDG (Fluorodeoxyglucose) Completed NCT02173964 Phase 4 pinaverium bromide;water
16 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide Completed NCT02149628 Phase 4 propofol;Desflurane
17 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
18 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
19 Evaluation of National Cancer Institute (NCI) Smoking Intervention Resources Completed NCT01342523 Phase 4
20 Bioactive Glass Granules in Filling of Bone Defects Completed NCT01304121 Phase 4
21 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
22 A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphami Completed NCT01636947 Phase 4 Aprepitant;Aprepitant Placebo;Ondansetron;Dexamethasone;Ondansetron Placebo;Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
23 The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements Completed NCT02241083 Phase 4 Dopamine;Norepinephrine
24 An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) Completed NCT00092183 Phase 4 MK0869, aprepitant / Duration of Treatment: 3 days;Comparator: ondansetron / Duration of Treatment: 3 days
25 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
26 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
27 Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594) Completed NCT00687011 Phase 4 Palonosetron and Dexamethasone
28 Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting Completed NCT01481831 Phase 4 Palonosetron Hydrochloride;Palonosetron Hydrochloride
29 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 4 panobinostat;bortezomib;dexamethasone
30 Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED) Completed NCT00684463 Phase 4 Palonosetron
31 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage Completed NCT00745095 Phase 4 Neostigmine
32 Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
33 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment Completed NCT01372904 Phase 4 Dexamethasone Phosphate
34 Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines Completed NCT01087905 Phase 4 Nicotine patch;Nicotine gum
35 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
36 Neurokinin Receptor Antagonist Associated to Ondansetron in PONV Completed NCT02357693 Phase 4 Aprepitant
37 A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis Completed NCT01382940 Phase 4 rituximab;methotrexate;methylprednisolone;acetaminophen;antihistamine
38 Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) Completed NCT00090207 Phase 4 MK0869, aprepitant / Duration of Treatment: 3 days;Comparator: ondansetron / Duration of Treatment: 4 days
39 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
40 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
41 COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined Completed NCT01361789 Phase 4 parecoxib, valdecoxib, etoricoxib;Dexamethasone;parecoxib, valdecoxib, parecoxib and dexamethasone
42 Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study Completed NCT01853787 Phase 4 Formoterol Fumarate;Salmeterol
43 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
44 Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea Completed NCT00781768 Phase 4 Standard PO ondansetron + dexamethasone;aprepitant (MK-869) + PO ondansetron + dexamethasone
45 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Recruiting NCT02056405 Phase 4 Mosapride;Placebo
46 Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites Recruiting NCT03315910 Phase 4 Nicotine Replacement Therapy (NRT);Nicotine Lozenge
47 Investigation of Sugammadex in Outpatient Urological Procedures Recruiting NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
48 Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery Recruiting NCT03172988 Phase 4 Dexamethasone;Normal saline;Flurbiprofen axetil;Lipid microsphere
49 Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery Recruiting NCT03200600 Phase 4 Dexamethasone;Normal saline;Flurbiprofen axetil;Lipid microsphere
50 Preoperative Brimonidine on IOP of Patients Undergoing RALP Recruiting NCT02818816 Phase 4 brimonidine tartrate 0.2%

Search NIH Clinical Center for Autonomic Nervous System Neoplasm

Genetic Tests for Autonomic Nervous System Neoplasm

Anatomical Context for Autonomic Nervous System Neoplasm

MalaCards organs/tissues related to Autonomic Nervous System Neoplasm:

39
Breast, Prostate, Lung, Bone, B Cells, T Cells, Bone Marrow

Publications for Autonomic Nervous System Neoplasm

Variations for Autonomic Nervous System Neoplasm

Expression for Autonomic Nervous System Neoplasm

Search GEO for disease gene expression data for Autonomic Nervous System Neoplasm.

Pathways for Autonomic Nervous System Neoplasm

Pathways related to Autonomic Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.76 AKT1 CASP3 MYC NGF NTRK1 TP53
2
Show member pathways
12.73 AKT1 CASP3 NGF NTRK1 NTRK2 TP53
3 12.61 AKT1 CASP3 MYC NTRK1 TP53
4 12.49 AKT1 CASP3 MYC NGF NTRK1 NTRK2
5
Show member pathways
12.44 AKT1 CASP3 MYC TP53
6
Show member pathways
12.37 AKT1 CASP3 NTRK1 NTRK2 TP53
7 12.24 AKT1 CASP3 MYC TP53
8 12.17 MYC MYCN NTRK1 TP53
9 12.12 AKT1 CASP3 MYC TP53
10 12.1 CASP3 NGF NTRK2 PHOX2B TH
11 12.08 AKT1 CASP3 MYC TP53
12
Show member pathways
12.02 AKT1 CASP3 MFRP MYC NTRK1 NTRK2
13 12.01 AKT1 CASP3 NGF NTRK1 NTRK2
14
Show member pathways
11.81 AKT1 CASP3 MYC NGF NTRK1 TP53
15 11.76 AKT1 CASP3 MYC TP53
16
Show member pathways
11.75 AKT1 MYC VIP
17 11.74 BACE1 ENO2 MYCN NGF NTRK1 NTRK2
18 11.67 AKT1 CASP3 TP53
19
Show member pathways
11.64 AKT1 CASP3 NGF TP53
20 11.62 AKT1 MYC NTRK1 TP53
21
Show member pathways
11.58 NGF NTRK1 NTRK2
22 11.51 AKT1 BACE1 CASP3 TP53
23 11.41 BACE1 NTRK1 NTRK2
24 11.41 AKT1 CASP3 MYC TP53
25 11.33 AKT1 CASP3 MYC TP53
26 11.25 AKT1 CASP3 NGF
27 11.17 AKT1 CNTN6 MYC MYCN TP53
28 10.79 CASP3 NTRK2
29
Show member pathways
10.65 NGF NTRK1 NTRK2
30 10.3 MYC MYCN

GO Terms for Autonomic Nervous System Neoplasm

Biological processes related to Autonomic Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.95 AKT1 CASP3 MYC NGF TP53
2 positive regulation of gene expression GO:0010628 9.88 MYC MYCN NGF NTRK2 TP53
3 positive regulation of cell proliferation GO:0008284 9.86 MYC MYCN NTRK2 VIP
4 nervous system development GO:0007399 9.85 AKT1 ALK CNTN6 NTRK1 NTRK2 NUMBL
5 protein autophosphorylation GO:0046777 9.8 AKT1 ALK NTRK1 NTRK2
6 cellular response to drug GO:0035690 9.71 MYC TH TP53
7 neuron differentiation GO:0030182 9.71 CASP3 CNTN6 NTRK2 PHOX2B
8 cellular response to growth factor stimulus GO:0071363 9.69 AKT1 NTRK1 TH
9 response to nicotine GO:0035094 9.61 CASP3 NTRK1 TH
10 cellular response to nicotine GO:0071316 9.52 NTRK1 TH
11 response to gamma radiation GO:0010332 9.5 MYC TP53 TRIM13
12 mechanoreceptor differentiation GO:0042490 9.46 NTRK1 NTRK2
13 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.46 ALK NGF NTRK1 NTRK2
14 neurotrophin signaling pathway GO:0038179 9.26 NTRK1 NTRK2
15 phosphatidylinositol-mediated signaling GO:0048015 9.26 AKT1 NGF NTRK1 TP53
16 neurotrophin TRK receptor signaling pathway GO:0048011 8.8 CASP3 NGF NTRK1

Molecular functions related to Autonomic Nervous System Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 ALK NTRK1 NTRK2
2 neurotrophin binding GO:0043121 8.96 NTRK1 NTRK2
3 neurotrophin receptor activity GO:0005030 8.62 NTRK1 NTRK2

Sources for Autonomic Nervous System Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....